Anavex Life Sciences Corp (AVXL)

[sokol]

I sent this to the WSJ:

Dear Daniela:

I have been a long time WSJ subscriber. I encourage you and others to become more comfortable in researching and writing about innovative drugs that have possibilities rather than to continue to dwell on mainstream big pharma drugs that do not work. The Lilly "throw in the towel" PR this week about its amyloid plaque drug, solanezunab, is a capitulation that the amyloid theory approach to combatting Alzheimer's has not worked to arrest the Alzheimer's epidemic.

''While there is no cure, prevention or treatment to slow the progression of Alzheimer's disease, there are five prescription medications approved by the U.S. Food and Drug Administration (FDA) to treat its symptoms.''...... http://www.alz.org/i-have-alz/treatments-and-research.asp. None of the five FDA Alzheimer's approved drugs work to alter the progression of the disease.

On Nov. 22, 2016 of this very same week Anavex Life Sciences Corp. (AVXL) announced a positive 41-week update from its Phase 2a study in mild-to-moderate Alzheimer’s disease (AD) patients for ANAVEX 2-73, which targets cellular homeostasis.

Anavex Life Sciences Announces Data on 41-Week Treatment of ANAVEX 2-73 for Patients with Alzheimer’s Disease - Investigational Treatment suggests to curb Cognitive and Functional Decline.

Read more: http://www.nasdaq.com/press-release/anavex-life-sciences-announces-data-on-41week-treatment-of-anavex-273-for-patients-with-alzheimers-20161122-00252#ixzz4QwSDtLT5

''At 41 weeks, Alzheimer’s patients taking a daily oral dose of ANAVEX 2-73 in the exploratory, not yet dose optimized Phase 2a clinical trial, showed a stabilization of cognitive and functional measures. This data of stabilization is promising since Alzheimer’s disease is a progressive disease where current therapeutics are only able to temporarily slow the worsening of dementia symptoms and not stop the disease from progressing.''

It is interesting too that Anavex and Lily are scheduled to be present at the 9TH CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) DECEMBER 8-10, 2016. This seems to me to be an opportunity for a report about an alternative to the plaque amyloid theory.

Why not focus more on what may work than what does not work?

Thank you.